REN and primary aldosteronism: It is increasingly recognized that MRAs should be used in resistant hypertension and low-renin hypertension (and that in these categories 15–70% of patients may in fact have primary aldosteronism); there are compelling data for eplerenone as a potent hypotensive in essential hypertensives with normal plasma renin, aldosterone, and potassium [28].